Allurion Technologies Holdings Inc. has released its financial results for the first quarter of 2025. The company reported total revenue of $5.6 million for the quarter ended March 31, 2025, compared to $9.4 million in the same period of 2024. Operating expenses for the quarter were $11.4 million, a significant reduction from $18.3 million in the previous year. The adjusted operating expenses were $10.1 million, excluding $1.4 million of one-time costs related to financings. The company reported a net operating loss of $7.3 million, a 36% decrease compared to the prior year, with an adjusted net operating loss of $5.9 million, marking a 48% reduction compared to the previous year. The gross margin improved to 75% from 73% in the prior year. Allurion has maintained its 2025 revenue guidance of approximately $30 million, while projecting a reduction in operating expenses by approximately 50% compared to 2024. In addition, the company has made progress on its business operations, having presented topline AUDACITY results to the FDA, completed a Pre-PMA meeting, and is on track to submit the final module of PMA by the end of June. Furthermore, Allurion has selected sites and drafted a protocol for a prospective trial on the combination of the Allurion Program with low-dose GLP-1 medications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.